TD Cowen Raises Halozyme Therapeutics (HALO) Price Target to $130

TD Cowen reiterated its Buy rating for Halozyme Therapeutics with a new price target of $130 on October 13, 2026, a 7% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:29 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen raised its price target on Halozyme Therapeutics, Inc. ($HALO) to $130 from $105 on October 13, 2026, and rates the stock "Buy".

Since the rating, $HALO is up 11.2% to date (from the $109.62 close on Oct 13, 2026).

HALO Halozyme Therapeutics, Inc.

$121.84 +73.29% year to date

Daily close · Oct 16, 2026

Key Points

TD Cowen has reiterated its Buy rating on Halozyme Therapeutics, raising the price target from $105 to $130 as of October 13, 2026.
TD Cowen's $130 price target implies 7% upside from Halozyme Therapeutics, Inc.'s ($HALO) current $121.49 share price.
The stock recently traded at $121.49, which is about 6.5% below the new price target set by TD Cowen.
Halozyme's trailing twelve-month revenue reached approximately $1.66 billion, with a strong revenue growth rate of 47.7% year-over-year.

Get $HALO trade alerts by text

We text you when insiders, Congress or big funds trade $HALO. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Halozyme Therapeutics, Inc. alert may contain errors. Disclosures

TD Cowen reiterated its Buy rating for Halozyme Therapeutics, Inc. (NasdaqGS: HALO) on October 13, 2026, increasing the price target from $105 to $130. This change indicates the firm's confidence in the company's future growth prospects, particularly in the biotechnology sector where it operates.

Analyst rating track record

TD Cowen vs. the S&P 500

YTD return +2.96% hypothetical

All-time return +2.96% S&P 500 +0.46%

vs. S&P 500 +2.50% ahead of the index

Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.

TD Cowen's Call on Halozyme

In its latest research note, TD Cowen maintained a Buy rating on Halozyme Therapeutics while adjusting the price target to $130. This marks a notable increase from the previous target of $105. The stock was recently trading at $121.49, which is about 6.5% below the new target.

Other Institutional Activity in Halozyme

Several other institutional investors have shown interest in Halozyme. BlackRock Inc. holds 13,271,095 shares valued at approximately $1.62 billion after a slight increase of 6,632 shares. Vanguard Capital Management LLC owns 5,351,312 shares worth about $652 million, having added 80,122 shares. Similarly, Vanguard Portfolio Management LLC increased its stake by 49,867 shares, bringing its total to 5,299,008 shares valued at around $646 million. State Street Corporation also boosted its holdings, adding 241,467 shares for a total of 5,179,434 shares valued at $631 million. In contrast, Invesco Ltd. reduced its stake by 834,625 shares, leaving it with 3,177,997 shares worth around $387 million.

Halozyme Therapeutics, Inc. Stock Holds Steady

Halozyme's stock is currently positioned below the new price target set by TD Cowen. The recent trading price of $121.49, as of October 16, 2026, reflects a solid position relative to its past performance. The company has shown strong revenue growth, which is a positive indicator for its future prospects in the biotechnology industry.

12-month forecast

$HALO price target

Halozyme Therapeutics, Inc. daily closes and this analyst's $130 target. Not advice.

Recent Earnings

Halozyme reported trailing twelve-month revenue of approximately $1.66 billion and an impressive revenue growth rate of 47.7% year-over-year. The company has also achieved a net margin of 24.9% and a return on equity of 173.7%. Its next earnings report is scheduled for November 2, 2026, which could provide further insights into its performance and growth.

Insider Buying and Selling at Halozyme Therapeutics, Inc.

Insider activity at Halozyme includes several sales by CEO Helen I. Torley. On October 8, 2026, she sold 60,000 shares valued at about $6.61 million. Earlier, on September 11 and August 19, she sold an equal number of shares, with values around $6.44 million and $6.28 million, respectively. Additionally, Director Matthew L. Posard sold 18,996 shares on September 16, 2026, valued at approximately $2.05 million. These transactions were all made before the recent analyst rating update.

Analysts Set New Price Targets

On October 13, 2026, TD Cowen reiterated its Buy rating on Halozyme with a new price target of $130. This follows several other recent analyst actions, including HC Wainwright & Co. maintaining a Buy rating with a target of $130 on October 8, 2026. The consensus among analysts suggests a positive outlook for Halozyme, with a mix of ratings indicating confidence in its growth potential.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on researching, developing, and commercializing proprietary enzymes and devices that enhance the delivery of injectable biologics. The company's products are built around its patented recombinant human hyaluronidase enzyme, which facilitates the administration of various therapeutic molecules.

Bottom Line

Investors should keep an eye on Halozyme's upcoming earnings report on November 2, 2026, as well as any further analyst updates. With a solid revenue growth trajectory and a positive rating from TD Cowen, the company's future performance will be closely watched.